Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5922790 | 0.89 | BCAT1 (0.67) | BCAT1BCAT2 | |
| SCHEMBL24824100 | 0.80 | BCAT1 (1.00) | BCAT1BCAT2 | |
| SCHEMBL29779220 | 0.80 | BCAT1 (1.00) | BCAT1BCAT2 | |
| SCHEMBL7653665 | 0.78 | BCAT1 (0.72) | BCAT1BCAT2 | |
| SCHEMBL29779349 | 0.78 | BCAT1 (0.62) | BCAT1BCAT2 | |
| SCHEMBL24826936 | 0.78 | BCAT1 (0.62) | BCAT1BCAT2 | |
| SCHEMBL24825601 | 0.77 | BCAT1 (0.84) | BCAT1BCAT2 | |
| SCHEMBL29779296 | 0.77 | BCAT1 (0.84) | BCAT1BCAT2 | |
| SCHEMBL7696171 | 0.77 | BCAT1 (0.53) | BCAT1BCAT2 | |
| SCHEMBL24824854 | 0.77 | BCAT1 (0.84) | BCAT1BCAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411381-A1 | PYRIMIDINEDIONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-29 | — | — | US | disclosed |
| US-20220411381-A1 | PYRIMIDINEDIONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-29 | — | — | US | disclosed |
| EP-4038054-A1 | PYRIMIDINEDIONE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411381-A1 | PYRIMIDINEDIONE DERIVATIVES | DPYD, TYMP, TYMS | BCAT1 2999/4885BCAT2 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.